Clinical data | |
---|---|
Other names | Laudolissin |
Routes of administration | IV |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 100% (IV) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C54H80N2O16S2 |
Molar mass | 1077.35 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Laudexium metilsulfate is a neuromuscular blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in surgical anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Laudexium[1] is no longer used in clinical practice, though it was introduced clinically in the early 1950s.[citation needed] It has about half the potency, a slower onset of action and a duration of action much longer than that of d-tubocurarine.[2] As with all clinically established (as well as experimental agents) with a non-depolarizing mechanism of action, its pharmacological action can be antagonized by anticholinesterases.
The displacement of laudexium from clinical use was assured owing to recurrent reports of significant post-operative re-curarization.[3]